Zembrace SymTouch FDA Approval History
Zembrace SymTouch (sumatriptan) is a selective 5-HT1B/ID receptor agonist in a prefilled, ready-to-use, single-dose disposable autoinjector for the treatment of acute migraine episodes, with or without aura.
Development Timeline for Zembrace SymTouch
|Jan 29, 2016||Approval Dr. Reddy’s Laboratories Ltd. Receives FDA Approval for Zembrace SymTouch (sumatriptan succinate) Injection for the Acute Treatment of Migraines|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.